Printed From BioPortfolio.com
TESARO announces EC approval of ZEJULA for recurrent ovarian cancer
15:24 EST 20 Nov 2017 | CentreWatch
TESARO, an oncology focused biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for ZEJULA (niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response (CR) or partial response (PR) to platinum-based chemotherapy. ZEJULA […]
The post TESARO announces EC approval of ZEJULA for recurrent ovarian cancer appeared first on CenterWatch News Online.
Original Article: TESARO announces EC approval of ZEJULA for recurrent ovarian cancer
